Swiss National Bank
RCUS icon

Swiss National Bank’s Arcus Biosciences RCUS Stock Holding History

Swiss National Bank’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.7M Buy
171,296
+3,300
+2% +$71.3K ﹤0.01% 1519
2025
Q4 		$4M Buy
167,996
+34,500
+26% +$704K ﹤0.01% 1481
2025
Q3 		$1.82M Buy
133,496
+12,200
+10% +$127K ﹤0.01% 1908
2025
Q2 		$987K Sell
121,296
-12,300
-9% -$105K ﹤0.01% 2151
2025
Q1 		$1.05M Buy
133,596
+35,300
+36% +$409K ﹤0.01% 2108
2024
Q4 		$1.46M Hold
98,296
– – ﹤0.01% 2032
2024
Q3 		$1.5M Hold
98,296
– – ﹤0.01% 2010
2024
Q2 		$1.5M Buy
98,296
+2,900
+3% +$46.8K ﹤0.01% 1958
2024
Q1 		$1.8M Hold
95,396
– – ﹤0.01% 1893
2023
Q4 		$1.82M Sell
95,396
-9,000
-9% -$144K ﹤0.01% 1900
2023
Q3 		$1.87M Buy
104,396
+9,100
+10% +$183K ﹤0.01% 1881
2023
Q2 		$1.94M Buy
95,296
+1,600
+2% +$30.5K ﹤0.01% 1913
2023
Q1 		$1.71M Sell
93,696
-10,800
-10% -$206K ﹤0.01% 1938
2022
Q4 		$2.16M Buy
104,496
+2,500
+2% +$68.8K ﹤0.01% 1850
2022
Q3 		$2.67M Buy
101,996
+1,500
+1% +$39.7K ﹤0.01% 1675
2022
Q2 		$2.55M Buy
100,496
+9,200
+10% +$225K ﹤0.01% 1749
2022
Q1 		$2.88M Buy
91,296
+4,800
+6% +$161K ﹤0.01% 1812
2021
Q4 		$3.5M Buy
86,496
+600
+0.7% +$23.3K ﹤0.01% 1698
2021
Q3 		$3M Hold
85,896
– – ﹤0.01% 1786
2021
Q2 		$2.36M Sell
85,896
-10,600
-11% -$303K ﹤0.01% 1999
2021
Q1 		$2.71M Buy
96,496
+1,100
+1% +$38.3K ﹤0.01% 1828
2020
Q4 		$2.48M Buy
95,396
+11,600
+14% +$281K ﹤0.01% 1787
2020
Q3 		$1.44M Buy
83,796
+1,300
+2% +$29K ﹤0.01% 1885
2020
Q2 		$2.04M Buy
82,496
+37,996
+85% +$1.03M ﹤0.01% 1702
2020
Q1 		$618K Buy
44,500
+1,300
+3% +$16.2K ﹤0.01% 2084
2019
Q4 		$436K Hold
43,200
– – ﹤0.01% 2449
2019
Q3 		$393K Hold
43,200
– – ﹤0.01% 2419
2019
Q2 		$343K Hold
43,200
– – ﹤0.01% 2496
2019
Q1 		$540K Hold
43,200
– – ﹤0.01% 2351
2018
Q4 		$465K Buy
+43,200
New +$504K ﹤0.01% 2378

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Swiss National Bank's RCUS Position: Q1 2026 in Review

Swiss National Bank increased its Arcus Biosciences (RCUS) stake by 2% in Q1 2026, buying an estimated $71.3K and bringing the position to 171,296 shares worth $3.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1519.

Swiss National Bank first reported a position in RCUS in Q4 2018 and has held it in 30 quarters since. The position peaked at $4M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Swiss National Bank held 171,296 shares of Arcus Biosciences worth $3.7M as of Q1 2026.
  • Swiss National Bank bought 3,300 Arcus Biosciences shares in Q1 2026, an estimated $71.3K.
  • Arcus Biosciences made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #1519 holding.
  • Swiss National Bank first reported a position in Arcus Biosciences in Q4 2018 and has held it in 30 quarters since.
  • Swiss National Bank's Arcus Biosciences position peaked at $4M in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.